Innovative complementary inhibitors qualified for fast-track treatment of acute autoimmune diseases

GBS is a rare acute autoimmune disease caused by nerve conduction damage caused by the patient's own immune system attacking his peripheral nervous systemIt usually occurs after an infectious disease and is characterized by the symmetry weakness of the limbsThe condition usually peaks within 4 weeksAt present, intravenous immunoglobulin (IVIg) and plasma replacement have been shown to be effective in treating GBSHowever, despite these treatments, many patients still have a residual neurological defect, accompanied by fatigue and chronic painCurrently, there are no approved treatments in the United Statescomplement system is an important immune regulation system in the body, the function of the complement system is abnormal or damaged will lead to the pathogenesis of many diseasesIt can participate in the body's anti-infection and immune regulation, can mediate immune pathological damage, and play a central role in the repair of damaged tissueC1q is an important component of complement C1 and can participate in the activation of the complement classical pathwayC1q acts directly with neuronal synapses in the central nervous system and causes neuronal damage and inflammationC1q can cause many diseases of ophthalmology, autoimmuneness, and neurodegenerative diseasesan ANX005 blocks activation of the classic pathway of complements (including C3 and C5) (Photo Source: Annexon)The supplement inhibitor ANX005 developed by Annexon is a humanized monoclonal antibody for C1q, which is mainly used to block C1q, a key protein in the early progenitor cascade process of human immunityIt not only blocks the activation of the whole classical path, but also maintains the integrity of the function of other complement pathwaysANX005 effectively blocks neuropathy through C1q and treats patients with GBSIn addition, Annexon is developing ANX005 applications in the treatment of other autoimmune and neurodegenerative diseases"Currently, there is no FDA-approved treatment for this debilitating neurodegenerative disease, " The FDA's fast-track qualification demonstrates the urgent need for new treatments to treat GBS patients," said Doug Love, President and CEO of Annexon References: